The current work designed a transferrin-conjugated BP-based nanoplatform co-loaded with doxorubicin and functionalized with PDA, offering active tumour targeting, pH/NIR-triggered release, and enhanced therapeutic synergy through chemo–photothermal–photodynamic modalities. The gene discussed is TF; the disease is neoplasm.